Research overview based on the cited scientific literature.

• Goal: Support cellular energy metabolism, DNA repair pathways, and mitochondrial function through exogenous NAD+ supplementation[1].

• Storage: Lyophilized powder frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F) for up to 14 days; protect from light.

Proper storage is critical to preserve NAD+ stability and potency.
• Lyophilized (Unopened): Store at −20 °C (−4 °F) or below (ideally −80 °C for multiyear storage) in a dry, dark environment[6]. Minimize moisture exposure as NAD+ powder is hygroscopic.
• Reconstituted Solution: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within approximately 14 days[7]. Keep protected from light (UV exposure degrades NAD+).
• Avoid Freeze–Thaw Cycles: Do not repeatedly freeze and thaw reconstituted NAD+ solution, as this reduces potency.
• Inspection: Before each use, inspect the solution for clarity. A fresh NAD+ solution should be clear and colorless. Discard if discoloration, cloudiness, or precipitate develops.

NAD+ is a coenzyme central to redox reactions, energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), and cellular maintenance pathways including DNA repair and mitochondrial biogenesis[1]. Cellular NAD+ levels decline with age and metabolic stress, which may contribute to reduced mitochondrial function and impaired cellular resilience[8].
Clinical research on NAD+ therapy has primarily used intravenous infusions at high doses (500–1,000 mg) for applications such as addiction treatment and acute metabolic support[2][9]. A pilot metabolic study demonstrated that a 750 mg NAD+ IV infusion over 6 hours was welltolerated in humans, with rapid metabolic clearance and no acute toxicity[10]. However, IV administration requires clinical supervision and specialized equipment.
The intravenous pilot measured plasma and urine metabolites during a six-hour infusion[10]. It did not evaluate subcutaneous self-injection or demonstrate a maintenance regimen.

Observations from preclinical models and clinical case reports.
Potential Benefits (Reported in Literature)
• May support cellular energy production and mitochondrial function through replenishment of NAD+ pools[1][8].
• Findings require attribution to the actual study, population and route; this overview does not provide a personal cognitive-support or metabolic-health regimen.
• Highdose IV protocols (500–1,500 mg daily for ~10 days) have been used in openlabel studies for substance use disorder, with reports of reduced cravings and improved mood in followups[2][9].
• The cited small intravenous pilot reported no adverse events during its six-hour observation period[10]. That limited observation does not establish long-term safety or safety by other routes.
Potential Side Effects
• Adverse-event findings must be assessed in the formulation, population and follow-up period studied; this overview does not recommend dose escalation.
• Mild injectionsite reactions (redness, itching, soreness) may occur with subcutaneous administration; human route-specific evidence is required.
• Some individuals report transient headache or flushing; these effects are generally dosedependent.
• This overview does not recommend a personal dose threshold or a therapeutic administration plan.